News and Events

On September 19 (US Time), the 2025 edition of the World's Top 2% Scientists list, a collaborative effort between a team led by Professor John P.A. Ioannidis of Stanford University and Elsevier, was released. Dr. Chen Shifu, Founder&CTO of HaploX, has been recognized in both the "Career-Long Impact" list and the "2025 Single-Year Impact" list. This marks the fourth consecutive year (2022-2025) that Dr. Chen has been selected for the annual scientific impact list. In the 2025 rankings, Dr. Chen holds a remarkable global position of 4,762, placing him within the top 0.05% of nearly ten million scholars worldwide. Furthermore, among researchers specifically in the field of Bioinformatics, he ranks within the global top 50.

The World's Top 2% Scientists list identifies the world's most influential researchers by evaluating a comprehensive set of parameters, including citation metrics, the h-index, the co-authorship-adjusted hm-index, and citations to papers as single or first author. Drawing from a pool of nearly 7 million scientists globally, this list aims to provide an objective and genuine reflection of a scientist's impact.

Dr. Chen Shifu's consistent recognition in the "World's Top 2% Scientists" lists underscores his outstanding achievements and sustained influence in scientific research. Dedicated to the field of bioinformatics, Dr. Chen initiated the OpenGene open-source project in 2016. Under this project, his team has developed over twenty bioinformatics software tools, which have gained significant popularity among users. Notably, the in-house developed FASTP software, renowned for its exceptional speed and high efficiency, has become an essential tool in bioinformatics. The academic paper describing Fastp has been cited over 20,000 times, ranking it among the most highly cited papers from China in the biological sciences in recent years. Leading his team to overcome technical challenges, Dr. Chen has driven continuous innovation, resulting in the development of HaploX's proprietary LIUDUS® integrated molecular diagnostics technology platform. He has also spearheaded the creation of multiple foundational NGS bioinformatics software and algorithms for variant calling, fusion detection, CNV analysis, and MSI detection in oncology, significantly enhancing the precision of HaploX's genetic testing technologies and fostering deep integration between Biotechnology (BT) and Information Technology (IT) within the company.

The complete 2025 World's Top 2% Scientists list is available at: 

https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/8